Drug profile · INN
golimumab
SIMPONI
golimumab (SIMPONI) is a tnf-alpha inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — golimumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
golimumab (SIMPONI) is a tnf-alpha inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
TNF-alpha inhibitor
Primary target: Tumor necrosis factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is golimumab?
golimumab (SIMPONI) is a tnf-alpha inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for golimumab?
SIMPONI is a marketed brand name for golimumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of golimumab?
golimumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.